Web-based decision tool in development to help high-risk patients decide if they want to undergo low dose CT screening for lung cancer.
A web-based decision-making tool for lung cancer screening (LCS) may help patients at high risk for lung cancer from smoking, say researchers from the University of Kentucky and the University of Miami.
While the National Lung Screening Trial (NLST) found that low-dose CT screening (LDCT) among people at high risk for lung cancer showed a 20 percent relative reduction in lung cancer mortality as compared to chest radiography, the report also noted substantial risks and limitations to LDCT, which include overdiagnosis and high false positive rates. The concern now is that patients may not be properly equipped to decide for or against LCS. The researchers’ proposed project is to develop a web-based decision aid that will help patients decide whether to undergo LCS.
“Screening is for asymptomatic healthy people to find out there’s something wrong,” Jamie Studts, PhD, researcher at the University of Kentucky, said in a release. “You are committing to a series of events that will lead to either learning you don’t have cancer, or detecting it and treating it.”[[{"type":"media","view_mode":"media_crop","fid":"26735","attributes":{"alt":"low dose lung CT","class":"media-image media-image-right","id":"media_crop_7067090008529","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"2526","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 142px; width: 150px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":" ","typeof":"foaf:Image"}}]]
The decision-making aid will provide information to the patients and empower the patients to talk to their physicians and make their decisions with the relevant information. A third objective involves clarifying the patient’s values: their personal preferences regarding screening and treatment. “The goal is to help people interpret what they learn in the context of what’s important to them regarding their goals in health,” Studts said. “They will learn about lung cancer screening options, benefits, harms, and uncertainties associated with the modality.”
A clinical trial for the decision aid will be held in Florida and Kentucky.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Enhanced Mobile CT System with High-Resolution Photon-Counting Technology
July 15th 2024Photon-counting CT-optimized features with the OmniTom Elite system include 30 cm field of view scanning, continuous spiral scanning, and an ultra-high-resolution capability of 0.141 mm resolution.